Clinical Trial Design Optimizer

AI-driven analysis identifies optimal subpopulations most likely to show treatment effect, with specific inclusion/exclusion criteria recommendations backed by historical evidence and biological rationale.

Data-driven recommendations for primary and secondary endpoints that balance regulatory acceptance, clinical meaningfulness, and statistical power.

Strategic analysis of how the trial fits within the company's broader portfolio and competitive landscape, with specific recommendations to differentiate from existing mechanisms of action.

Ingestion of proposed inclusion/exclusion criteria from third party or internal documents to build patient recruitment profiles. Conversational AI for clinical trial management to enhance patient access to clinical trials by improving trial matching accuracy.

Assessment of proposed design elements against successful regulatory precedents to maximize approval probability.

Quantification of how design choices affect the overall portfolio value and strategic positioning.

An AI-powered trial design optimizer is an agentic platform that uses artificial intelligence to streamline and improve the clinical trial design process. It integrates historical data, real-world evidence, and regulatory precedents to support better decision-making, reduce costs, and accelerate timelines.

Our solution enhances trial success by aligning protocol design with regulatory standards, optimizing patient selection using predictive models, and ensuring endpoints are clinically relevant and statistically robust—all within a data-driven framework.

Yes. By automating trial design tasks and improving protocol accuracy, AI solutions like Caylent’s Trial Design Optimizer can reduce trial execution costs by up to 20% and accelerate development timelines by 5–10%.

Absolutely. Caylent’s platform is built to adapt to your unique data environment and therapeutic focus, offering a fully customized AI-driven system tailored to your organization’s specific clinical development needs.

Investing in AI for clinical trial design helps life sciences companies stay competitive by reducing trial failure rates, improving portfolio value, and enabling smarter, faster decisions based on integrated, real-time data.